Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment
about
Type 2 Diabetes and ADP Receptor Blocker TherapyPersonalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfallsState-of-the-Art: Hypo-responsiveness to oral antiplatelet therapy in patients with type 2 diabetes mellitus.Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes.Long-term incidence and prognostic factors of the progression of new coronary lesions in Japanese coronary artery disease patients after percutaneous coronary interventionMean platelet volume changes before and after glycated hemoglobin (HbA1c) improvement in a large study population.A novel small molecule 1,2,3,4,6-penta-O-galloyl-α-D-glucopyranose mimics the antiplatelet actions of insulinRacial differences in resistance to P2Y12 receptor antagonists in type 2 diabetic subjectsClopidogrel "resistance": where are we now?In-hospital daily insulin dose predicts long-term adverse outcome in patients with diabetes with ST-elevation myocardial infarction treated with successful primary percutaneous angioplastyA pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial.Detection of clopidogrel hyporesponsiveness using a point-of-care assay and the impact of additional cilostazol administration after coronary stent implantation in diabetic patients.Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspectiveInterleukin-6 and asymmetric dimethylarginine are associated with platelet activation after percutaneous angioplasty with stent implantation.Diabetes mellitus and platelet reactivity in patients under prasugrel or ticagrelor treatment: an observational studyThe Influence of Haemoglobin A1c Levels on Platelet Aggregation and Platelet Turnover in Patients with Coronary Artery Disease Treated with AspirinIncreased atherothrombotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antiplatelet therapyClopidogrel resistance response in patients with coronary artery disease and metabolic syndrome: the role of hyperglycemia and obesity.Postprandial platelet activation is related to postprandial plasma insulin rather than glucose in patients with type 2 diabetes.Association between insulin receptor substrate-1 polymorphisms and high platelet reactivity with clopidogrel therapy in coronary artery disease patients with type 2 diabetes mellitus.Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetesPlatelet function testing to predict hyporesponsiveness to clopidogrel in patients with chest pain seen in the emergency department.Systematic review and meta-analysis of optimal P2Y12 blockade in dual antiplatelet therapy for patients with diabetes with acute coronary syndromeDiabetes mellitus: a prothrombotic state implications for outcomes after coronary revascularizationEstablishing a predictive model for aspirin resistance in elderly Chinese patients with chronic cardiovascular diseaseThe role of glucose lowering agents on restenosis after percutaneous coronary intervention in patients with diabetes mellitus.Aspirin and Diabetes Mellitus: revisiting an old player.Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions.Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention.P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use.Platelet reactivity and nonresponse to dual antiplatelet therapy: a review.Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations.Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis.Factors associated with clopidogrel nonresponsiveness.Residual platelet reactivity: predicting short- and long-term clinical outcome in patients undergoing percutaneous coronary revascularization.Antithrombotic therapy in patients with diabetes mellitus and coronary artery disease.Clinical value of antiplatelet therapy in patients with acute coronary syndromes and in percutaneous coronary intervention.The role of antiplatelets in hypertension and diabetes mellitus.Antiplatelet drug therapy: role of pharmacodynamic and genetic testing.Current concepts on coronary revascularization in diabetic patients.
P2860
Q26772996-7FC55579-57BF-4106-A4B0-8844A5E2ED0AQ26775125-2AF505F4-FEF4-4B2F-9AC9-696F07EAE9ACQ30373414-6FD5A7DF-2F17-4DA6-9CA6-42FE4A3DE62FQ33835709-95301895-A0C6-4097-981D-CEDA6D9C5766Q33858332-D31BD436-47C3-47B1-B399-BAD6DAAEE045Q33904436-5F2B67E7-2446-475A-99D1-BAD8A83A8C41Q34071537-9B8D6151-7FD7-40EA-9323-294D9CF91FDAQ34186272-CBEBFBF7-2A28-4F64-ACCF-D62591611AE4Q34212563-C975EF0A-0046-4E43-8B3C-B2359C70C52CQ34466743-89DEAA7E-5759-4718-8A86-6EB31F43344AQ34751965-3C1E8ED5-1732-42A3-9DD0-F1966ED7979EQ35033557-828F4BF0-FC62-4DD5-8A80-21137CD6E10FQ35174193-2A5DDD97-C3D7-440C-B9F5-A1C2F1C15861Q35216871-DF3D83C8-0FF0-4D09-BFAB-B91FCE076ACFQ35677083-9DF8CF51-0DE6-4D0C-A733-F5BDE31BDF05Q35684231-A9184753-69F1-4BAD-BD64-61D8FFD7B541Q35755253-D6D272C3-992C-4BB1-8B03-CC80F986E336Q36011287-E868A29B-E0A3-493E-9C2E-111C2481E4C3Q36182535-09FAA2F8-95C4-486E-BDC8-F20DA43246B2Q36720281-763BF4C3-368A-433A-871C-1B53408603B4Q36730207-7989344E-0752-42A8-9EC7-8491563AAA83Q36822610-1D8DEA80-2F05-4DC9-9B8F-ABAF5ACD584CQ36841959-14ACEC82-3BF3-4B55-A764-71418C80BD26Q37167506-35A266D3-656D-46E2-858A-C4BB2015DEBCQ37174269-84292D60-731A-43D7-9AC4-8FA89D4C794FQ37306857-089CE723-18D3-472C-89C7-A0C9D42C1407Q37362710-750B4E8C-5603-444B-815F-009DB907C5BEQ37428365-0945E71A-3244-403C-870C-CB3F3D103B91Q37451509-B19DF40A-2FF3-4439-AFE2-B82CD15E48F6Q37562606-42B49D5E-17C6-4DDC-A52F-6B7BDCF185B9Q37618798-4999D327-FFE0-46F8-BC66-F794B08B64B7Q37627874-64283434-FA20-4234-A27F-A8F19716A7E7Q37693951-13B60E1A-A396-45DB-8C6B-AF6C9602D459Q37709405-2FC82507-283F-4727-9D29-B8FCA6294F10Q37765291-9251CD98-A447-4B4E-AAF7-7CAB74C6C5DDQ37797795-1ECDA216-CCB6-4551-ACD0-E5EEC6B7659AQ37841560-937DC1BE-6516-4554-8BA8-2213E6069920Q37861894-AA7E1E4E-F1DB-4CA4-BDDB-441BA3693EBBQ37882712-50B25533-1F6E-4F08-B1DA-2F5223FFE382Q37926750-D72B482A-6667-42D2-94FE-480A37A0E45B
P2860
Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Insulin therapy is associated ...... al oral antiplatelet treatment
@ast
Insulin therapy is associated ...... al oral antiplatelet treatment
@en
Insulin therapy is associated ...... al oral antiplatelet treatment
@nl
type
label
Insulin therapy is associated ...... al oral antiplatelet treatment
@ast
Insulin therapy is associated ...... al oral antiplatelet treatment
@en
Insulin therapy is associated ...... al oral antiplatelet treatment
@nl
prefLabel
Insulin therapy is associated ...... al oral antiplatelet treatment
@ast
Insulin therapy is associated ...... al oral antiplatelet treatment
@en
Insulin therapy is associated ...... al oral antiplatelet treatment
@nl
P2093
P3181
P1476
Insulin therapy is associated ...... al oral antiplatelet treatment
@en
P2093
Camino Bañuelos
Carlos Macaya
Celia Ramírez
Dominick J Angiolillo
Esther Bernardo
Fernando Alfonso
Javier Escaned
Manel Sabaté
Marco A Costa
Pilar Jimenez-Quevedo
P304
P3181
P356
10.1016/J.JACC.2006.03.038
P407
P577
2006-06-22T00:00:00Z